"Regulatory Predictability" Is Key Barrier To Orphan Drug Development, Social Security Head Astrue Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's new leadership should focus on improving the "regulatory predictability" for orphan drug development, Social Security Administration Commissioner Michael Astrue said during a discussion of orphan drug policy sponsored by Shire Pharmaceuticals, the National Chamber Foundation and the U.S. Chamber of Conference in Washington, D.C. June 5
You may also be interested in...
Orphans Wanted: FDA Offers New Ideas For Rare Disease Drug Development
Top review managers tell NORD conference they are eager to find ways to accelerate development and comercialization of orphan drugs. CDER’s Woodcock suggests new partnership models focused on translational researc h as key component. CBER’s Yetter notes flexibility of regulatory standards and creative ideas for trial design
Orphans Wanted: FDA Offers New Ideas For Rare Disease Drug Development
Top review managers tell NORD conference they are eager to find ways to accelerate development and comercialization of orphan drugs. CDER’s Woodcock suggests new partnership models focused on translational researc h as key component. CBER’s Yetter notes flexibility of regulatory standards and creative ideas for trial design
Soc. Security Admin. Seeks Industry Help In Speeding Orphan Drug Coverage
Sponsors of drugs to treat disabling illnesses have an opportunity to work with the Social Security Administration to simplify eligibility determinations that could in turn make it easier for patients to obtain Medicare coverage for their treatments